| Issue Date | Title | Author(s) |
| 2021-03-03 | A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma | Cheung, BB; Kleynhans, A; Mittra, R; Kim, PY; Holien, JK; Nagy, Z; Ciampa, OC; Seneviratne, JA; Mayoh, C; Raipuria, M; Gadde, S; Massudi, H; Wong, IPL; Tan, O; Gong, A; Suryano, A; Diakiw, SM; Liu, B; Arndt, GM; Liu, T; Kumar, N; Sangfelt, O; Zhu, S; Norris, MD; Haber, M; Carter, DR; Parker, MW; Marshall, GM |
| 2021-03-25 | An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability | Nagy, Z; Seneviratne, JA; Kanikevich, M; Chang, W; Mayoh, C; Venkat, P; Du, Y; Jiang, C; Salib, A; Koach, J; Carter, DR; Mittra, R; Liu, T; Parker, MW; Cheung, BB; Marshall, GM |
| 2019-11-01 | Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface | Koach, J; Holien, JK; Massudi, H; Carter, DR; Ciampa, OC; Herath, M; Lim, T; Seneviratne, JA; Milazzo, G; Murray, JE; McCarroll, JA; Liu, B; Mayoh, C; Keenan, B; Stevenson, BW; Gorman, MA; Bell, JL; Doughty, L; Hüttelmaier, S; Oberthuer, A; Fischer, M; Gifford, AJ; Liu, T; Zhang, X; Zhu, S; Gustafson, WC; Haber, M; Norris, MD; Fletcher, JI; Perini, G; Parker, MW; Cheung, BB; Marshall, GM |
| 2023-07 | Pyrimido[1,2-a]benzimidazoles as inhibitors of oncoproteins ubiquitin specific protease 5 and MYCN in the childhood cancer neuroblastoma. | Gadde, S; Kleynhans, A; Holien, JK; Bhadbhade, M; Nguyen, PLD; Mittra, R; Yu, TT; Carter, DR; Parker, MW; Marshall, GM; Cheung, BB; Kumar, N |
